Listing 3 - Actual negotiations

Indication:

Schizophrenia

Indication:

Lambert-Eaton Myasthenic Syndrome (LEMS)

Indication:

Metastatic breast cancer (HER2-positive) first-line treatment

Indication:

Extensive-stage small cell lung cancer (ES-SCLC) in adult patients, first-line treatment (in combination with etoposide and either carboplatin or cisplatin)

Indication:

Metastatic breast cancer (HER2-positive) in patients who have not received prior antiHER2 therapy or chemotherapy for metastatic disease

Indication:

Metastatic breast cancer (HER2-positive) in patients who have not received prior antiHER2 therapy or chemotherapy for metastatic disease

Indication:

Metastatic breast cancer (HER2-positive) in patients with who have not received prior antiHER2 therapy or chemotherapy for metastatic disease; Early Breast Cancer (EBC); Metastatic Breast Cancer (MBC); and Metastatic Gastric Cancer (MGC)

Indication:

Splenomegaly and/or disease-related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib

Indication:

Metastatic breast cancer (HER2-positive) in patients who have not received prior antiHER2 therapy or chemotherapy for metastatic disease

Indication:

Metastatic breast cancer (HER2-positive) in patients who have not received prior antiHER2 therapy or chemotherapy for metastatic disease